GlassScriptPhysician profile
Arthur Pettigrew
NPI 1699824482
$2,007.98
in general payments reported to CMS, 2019-2025
27 companies · $480 in 2025
The $480 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $14.90 · 2022: $17.12 · 2023: $423 · 2024: $415 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,317.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $296.65 | 2019-2025 | Mounjaro |
| Novo Nordisk INC | $198.36 | 2019-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $185.41 | 2019 | |
| Astellas Pharma US INC | $182.36 | 2019-2025 | Veozah |
| Amgen INC. | $175.55 | 2019-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $119.28 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.81 | 2019-2024 | Synjardy, Jardiance, Tradjenta |
| Abbvie INC. | $106.72 | 2023-2025 | |
| Dexcom, INC. | $69.85 | 2023-2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $57.14 | 2019-2024 | Airsupra |
| Axsome Therapeutics, INC. | $56.58 | 2025 | Symbravo |
| Otsuka America Pharmaceutical, INC. | $51.04 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $50.89 | 2023 | |
| Janssen Pharmaceuticals, INC | $49.16 | 2023 | Xarelto |
| Glaxosmithkline, LLC. | $48.64 | 2019-2025 | Bexsero |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $46.32 | 2024 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $40.98 | 2019 | |
| Merck Sharp & Dohme LLC | $26.42 | 2019 | |
| Phathom Pharmaceuticals, INC. | $24.04 | 2024 | Voquezna |
| Shield Therapeutics INC | $17.82 | 2024 | |
| Exact Sciences Corporation | $16.43 | 2025 | |
| Phadia US INC. | $15.11 | 2025 | Immunocap |
| Hikma Pharmaceuticals USA | $14.07 | 2023 | Mitigare, Ryaltris |
| Allergan, INC. | $13.01 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.79 | 2023 | Quviviq |
| Corcept Therapeutics | $12.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Pettigrew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.